Serotype-Specific Pneumococcal Status prior to PCV 13 Administration in Children and Adolescents with Inflammatory Bowel Disease.
The aim of this study was to evaluate the serotype-specific pneumococcal status of children and adolescents with inflammatory bowel disease (IBD) who were naïve to pneumococcal vaccination before administering the 13-valent pneumococcal conjugate vaccine (PCV 13). This was an open, prospective study on children and adolescents aged 5-18 years who had IBD and were naïve to pneumococcal vaccination. A single dose of PCV 13 was administered to each patient. The geometric mean concentrations (GMCs) were measured for all 13 serotypes. A total of 122 subjects completed the study. Prevaccination GMCs ranged from 0.55 μg/ml (serotype 4) to 4.26 μg/mI (serotype 19A). Prior to the administration of PCV 13, high GMCs were detected in older children and adolescents who had IBD and were naïve to pneumococcal vaccination.
Aleksandra
A
Banaszkiewicz
Brygida
B
Targońska
Kinga
K
Kowalska-Duplaga
Katarzyna
K
Karolewska-Bochenek
Agnieszka
A
Sieczkowska
Agnieszka
A
Gawrońska
Urszula
U
Grzybowska-Chlebowczyk
Elzbieta
E
Krzesiek
Izabella
I
Łazowska-Przeorek
Maria
M
Kotowska
Edyta
E
Sienkiewicz
Jarosław
J
Walkowiak
Hanna
H
Gregorek
Andrzej
A
Radzikowski
Piotr
P
Albrecht
D000293:Adolescent; D000907:Antibodies, Bacterial / Q000097:blood; D002353:Carrier State; D002648:Child; D002675:Child, Preschool; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000382:microbiology*; D022242:Pneumococcal Vaccines / Q000276:immunology*; D065288:Serogroup; D013296:Streptococcus pneumoniae / Q000145:classification* / Q000302:isolation & purification
D000907:Antibodies, Bacterial; D022242:Pneumococcal Vaccines